Hepatitis C Virus and Liver Transplantation

Area of Science:

• Hepatology
• Virology
• Transplantation Medicine

Background:

• Hepatitis C virus (HCV) remains a significant cause of mortality and a leading indication for liver transplantation.
• Direct-acting antiviral (DAA) therapies have transformed HCV treatment, achieving high cure rates.
• DAA safety and tolerability facilitate HCV treatment in pre- and post-liver transplant patients.

Purpose of the Study:

• To review current direct-acting antiviral (DAA) therapies for Hepatitis C virus (HCV).
• To emphasize the applicability of DAAs in liver transplant recipients and patients with decompensated cirrhosis.
• To discuss optimizing HCV treatment in challenging liver transplant settings.

Main Methods:

• Review of published data on DAA therapies for HCV.
• Analysis of DAA efficacy and safety in liver transplant recipients.
• Evaluation of treatment modifications in specific patient populations.

Main Results:

• DAA therapies demonstrate high cure rates (>90%) for Hepatitis C virus (HCV).
• DAAs are safe and well-tolerated in liver transplant settings.
• Certain patient profiles may necessitate extended treatment durations or combination therapy.

Conclusions:

• HCV treatment in liver transplant recipients requires individualized approaches.
• DAA regimens can be effectively applied in patients with decompensated cirrhosis and liver transplant recipients.
• Optimizing DAA therapy may involve adjusting treatment duration or adding ribavirin.